Kazama JJ - Search Results

1

Overview of regular dialysis treatment in Japan (as of 31 December 2011).

Nakai S, Watanabe Y, Masakane I, Wada A, Shoji T, Hasegawa T, Nakamoto H, Yamagata K, Kazama JJ, Fujii N, Itami N, Shinoda T, Shigematsu T, Marubayashi S, Morita O, Hashimoto S, Suzuki K, Kimata N, Hanafusa N, Wakai K, Hamano T, Ogata S, Tsuchida K, Taniguchi M, Nishi H, Iseki K, Tsubakihara Y. Nakai S, et al. Among authors: kazama jj. Ther Apher Dial. 2013 Dec;17(6):567-611. doi: 10.1111/1744-9987.12147. Ther Apher Dial. 2013. PMID: 24330555

2

[PTH and bone metabolism in chronic dialysis patients].

Fukagawa M, Kazama J, Shigematsu T. Fukagawa M, et al. Rinsho Byori. 2001 Mar;49(3):236-8. Rinsho Byori. 2001. PMID: 11307321 Review. Japanese.

3

Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases.

Fukagawa M, Kazama JJ, Shigematsu T. Fukagawa M, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S152-5. doi: 10.1053/ajkd.2001.27426. Am J Kidney Dis. 2001. PMID: 11576943 Review.

4

Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients.

Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, Fukagawa M. Nakanishi S, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S172-4. doi: 10.1053/ajkd.2001.27436. Am J Kidney Dis. 2001. PMID: 11576948 Clinical Trial.

5

Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.

Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M. Kazama JJ, et al. Clin Exp Nephrol. 2003 Jun;7(2):144-9. doi: 10.1007/s10157-003-0226-2. Clin Exp Nephrol. 2003. PMID: 14586733

6

[Bone disease in secondary hyperparathyroidism].

Hayakawa H, Shigematsu T, Kazama JJ. Hayakawa H, et al. Among authors: kazama jj. Nihon Rinsho. 2004 Jun;62 Suppl 6:324-9. Nihon Rinsho. 2004. PMID: 15250317 Review. Japanese. No abstract available.

7

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Shigematsu T, et al. Among authors: kazama jj. Am J Kidney Dis. 2004 Aug;44(2):250-6. doi: 10.1053/j.ajkd.2004.04.029. Am J Kidney Dis. 2004. PMID: 15264182

8

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M. Nakanishi S, et al. Among authors: kazama jj. Kidney Int. 2005 Mar;67(3):1171-8. doi: 10.1111/j.1523-1755.2005.00184.x. Kidney Int. 2005. PMID: 15698459 Free article.

9

[The up-to-date of PTH assay: the progression and some clinical problem].

Shigematsu T, Kazama J, Hukagawa M. Shigematsu T, et al. Clin Calcium. 2002 Jun;12(6):759-63. Clin Calcium. 2002. PMID: 15775363 Japanese.

10

Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.

Kazama JJ. Kazama JJ. Ther Apher Dial. 2007 Oct;11 Suppl 1:S44-7. doi: 10.1111/j.1744-9987.2007.00516.x. Ther Apher Dial. 2007. PMID: 17976085

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters